Cybersecurity Surges, Biotech Booms & SaaS Shifts- 7 Hot Stocks Lighting Up into the Close

September 2, 2025

DENVER, Colo., Sep 02, 2025 (247marketnews.com)- As markets head into the final stretch, here’s your 24/7 Market News Power Hour guide:

Cycurion (NASDAQ:CYCU) is rallying after announcing it has regained Nasdaq compliance and reinforced confidence with a $69 million multi-year contract backlog. CEO Kevin Kelly argues this backlog, plus strong institutional partnerships, creates a “highly positive asymmetric risk/reward” scenario for investors.

TEN Holdings (NASDAQ:XHLD) is progressing its digital pivot with the Ten Events Pro beta—noted for “real-time control, broadcast‑quality visuals, and low‑cost scalability.” Industry watchers are positioning ahead of a potential breakout post-launch in 2026.

Launched in July 2025, the beta program offers enterprise clients exclusive early access to a platform promising real-time control, broadcast-quality visuals, and low-cost scalability. Unlike traditional production services, Ten Pro emphasizes automation and margin expansion, a potential game-changer for the Company’s revenue mix.

With an official public launch slated for early 2026, XHLD is positioning itself for high-margin SaaS revenue while expanding beyond its core event services business.

MannKind (NASDAQ:MNKD) is seeing elevated volatility as investors await insights from the company’s series of investor presentations. Historical model estimates show upside—from royalty streams tied to its Tyvaso DPI programs and orphan lung pipeline, could fuel aggressive upside if reiterated.

Up sharply mid-session, NovaBay Pharmaceuticals (NASDAQ:NBY) continues to catch traders’ eyes amid renewed interest in its synthetic anti-infective programs for eye-care and wound care, especially Avenova and NeutroPhase.

McEwen Mining Inc. (NYSE:MUX) & Hycroft Mining (NASDAQ:HYMC) are attracting capital flows as gold prices climb. MUX is holding near intraday highs, while HYMC is riding broad precious metals sentiment amid tailwinds in resource exposure.

Relmada Therapeutics (NASDAQ:RLMD) is in focus after its NDV‑01 Phase II study for bladder cancer showed 91% complete response rate at 6 months, an expansion from earlier 90% disease-free data. The company is now preparing for a Phase III trial early next year.

Please go to https://247marketnews.com/ten-holdings-event-solutions/ for additional 247marketnews.com XHLD disclosure

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CYCU, XHLD, MUX, HYMC, MNKD, NBY)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.